stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Free cash flow
BioNTech SE Sponsored ADR's free cash flow for fiscal 2025 was −$326.4M, compared with −$263.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$524.1M. Over the past ten years it has ranged from −$326.4M (fiscal 2025) to $13.9B (fiscal 2022) — the current reading is the lowest in ten years. Free cash flow has fallen for 3 consecutive fiscal years. BioNTech SE Sponsored ADR ranks 593rd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$326.4M | — |
| FY2024 | −$263.4M | — |
| FY2023 | $5.0B | (63.73%) |
| FY2022 | $13.9B | 1,492.24% |
| FY2021 | $874.4M | — |
| FY2020 | −$111.6M | — |
| FY2019 | −$301.9M | — |
| FY2018 | −$148.0M | — |
| FY2017 | −$59.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$197.2M | — |
| Jun 2026 | −$44.4M | — |
| Mar 2026 | −$583.2M | — |
| Dec 2025 | $300.7M | (63.67%) |
| 26 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $806.3M |
| INCY Incyte Corporation compare | $679.9M |
| ASND Ascendis Pharma A/S compare | $387.5M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.8M |
| BNTX BioNTech SE Sponsored ADR | −$524.1M |
| INSM Insmed, Inc. compare | −$627.6M |
| ROIV Roivant Sciences Ltd. compare | −$821.1M |
| GMAB Genmab A/S Sponsored ADR compare | −$6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement